Menu Search
Equities

Botanix Pharmaceuticals Ltd

BXPHF:PKC

Botanix Pharmaceuticals Ltd

Actions
  • Price (USD)0.22
  • Today's Change0.00 / 0.00%
  • Shares traded175.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 14:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

  • Revenue in AUD (TTM)677.54k
  • Net income in AUD-13.87m
  • Incorporated1984
  • Employees1.00
  • Location
    Botanix Pharmaceuticals LtdSuite 3, 41-47 Colin Street, West PerthPERTH 6005AustraliaAUS
  • Phone+61 86285-0083
  • Fax+61 86210-1153
  • Websitehttps://botanixpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.